Improved overall survival in melanoma with combined dabrafenib and trametinib.

@article{Robert2015ImprovedOS,
  title={Improved overall survival in melanoma with combined dabrafenib and trametinib.},
  author={C. Brooks Robert and Boguslawa Karaszewska and Jacob M Schachter and Piotr Z. Rutkowski and Andrzej Mackiewicz and Daniil Stroiakovski and Michael R Lichinitser and Reinhard Dummer and F Grange and Laurent Mortier and Vanna Chiarion-Sileni and Kamil Drucis and Ivana Krajsov{\'a} and Michal Starnawski and Paul C. Lorigan and Pascal Wolter and Georgina V. Long and Keith T Flaherty and Paul N. Nathan and Antoni Ribas and A. Mart{\'i}n and Peng Sun and Wendy A Crist and Jeffrey J. Legos and Stephen D. Rubin and Shonda M Little and Dirk Schadendorf},
  journal={The New England journal of medicine},
  year={2015},
  volume={372 1},
  pages={
          30-9
        }
}
BACKGROUND The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously untreated metastatic melanoma with BRAF V600E or V600K mutations. Combining dabrafenib and the MEK inhibitor trametinib, as compared with dabrafenib alone, enhanced antitumor activity in this population of patients. METHODS In this open-label, phase 3 trial, we randomly assigned 704 patients with metastatic melanoma with a BRAF V600 mutation to receive either a… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 650 CITATIONS, ESTIMATED 46% COVERAGE

Trametinib in the treatment of melanoma.

  • Expert opinion on biological therapy
  • 2015
VIEW 18 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2017
VIEW 4 EXCERPTS
CITES METHODS, BACKGROUND & RESULTS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2013
2019

CITATION STATISTICS

  • 38 Highly Influenced Citations

  • Averaged 117 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 28 REFERENCES

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010;468:968-72

CM Johannessen, JS Boehm, SY Kim
  • Copyright © 2014 Massachusetts Medical Society. The New England Journal of Medicine Downloaded from nejm.org at HAUPTBIBLIOTHEK UNIV ZUERICH on March
  • 2015

Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2014
VIEW 2 EXCERPTS